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Abstract
Background: Neonatal STZ treatment induces a state of mild hyperglycemia in adult rats that disrupts metabolism
and maternal/fetal interactions. The aim of this study was investigate the effect of neonatal STZ treatment on the
physical development, behavior, and reproductive function of female Wistar rats from infancy to adulthood.
Methods: At birth, litters were assigned either to a Control (subcutaneous (s.c.) citrate buffer, n = 10) or STZ group,
(streptozotocin (STZ) - 100 mg/kg-sc, n = 6). Blood glucose levels were measured on postnatal days (PND) 35, 84
and 120. In Experiment 1 body weight, length and the appearance of developmental milestones such as eye and
vaginal opening were monitored. To assess the relative contribution of the initial and long term effects of STZ
treatment this group was subdivided based on blood glucose levels recorded on PND 120: STZ hyperglycemic
(between 120 and 300 mg/dl) and STZ normoglycemic (under 120 mg/dl). Behavioral activity was assessed in
an open field on PND 21 and 75. In Experiment 2 estrous cyclicity, sexual behavior and circulating gonadotropin,
ovarian steroid, and insulin levels were compared between control and STZ-hyperglycemic rats. In all measures
the litter was the experimental unit. Parametric data were analyzed using one-way or, where appropriate, two-way
ANOVA and significant effects were investigated using Tukey’s post hoc test. Fisher’s exact test was employed when
data did not satisfy the assumption of normality e.g. presence of urine and fecal boli on the open field between
groups. Statistical significance was set at p < 0.05 for all data.
Results: As expected neonatal STZ treatment caused hyperglycemia and hypoinsulinemia in adulthood.
STZ-treated pups also showed a temporary reduction in growth rate that probably reflected the early loss of
circulating insulin. Hyperglycemic rats also exhibited a reduction in locomotor and exploratory behavior in the
open field. Mild hyperglycemia did not impair gonadotropin levels or estrous cylicity but ovarian steroid
concentrations were altered.
Conclusions: In female Wistar rats, neonatal STZ treatment impairs growth in infancy and results in mild
hyperglycemia/hypoinsulinemia in adulthood that is associated with changes in the response to a novel
environment and altered ovarian steroid hormone levels.
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Background
Several methods have been used to reproduce in laboratory
animals the hyperglycemic state of diabetic patients among
these is the administration of beta-cytotoxic chemical
agents, such as streptozotocin (STZ). STZ damages the
pancreatic beta-cell initially causing release of insulin lead-
ing to a transient hyperinsulinemia/hypoglycemia and then
resulting in longterm hypoinsulinemia/hyperglycemia [1].
Depending on the route, dose, age, and strain of animals,
STZ may induce severe or mild diabetes. When rats are
rendered diabetic using STZ administration during adult
life they present severe diabetes, with blood glucose levels
above 300 mg/dl and often exceeding 500 mg/dl. Glycemic
levels within this range are rare among the human diabetic
population. As a consequence, experimental manipulations
that result in animals presenting mild hyperglycemia
(between 120 and 300 mg/dL) have been developed
(see [2] for a review). In contrast to the permanent
effects of STZ seen following treatment of adult rats,
neonatal administration of this drug produces only a
transient effect on insulin levels because there is a
spontaneous recovery of the beta-cells over the first
2 weeks of life, resulting in normoglycemia until at
least 6–8 weeks of life. However, beta-cell regeneration
is often incomplete leading to reduced beta-cell mass [1],
impaired glucose tolerance and reduced plasma insulin in
adulthood [3].
Although a number of studies have shown the conse-
quences of neonatally STZ induced mild diabetes on
several metabolic parameters [1,3-10] little is known
about how this neonatal insult might affect physical
development or behavior in infancy and adult life. In
addition, although behavioral changes in the open field
[11-15] and compromised reproductive function [16,17],
including impaired sexual behavior [18-20], have been
reported in animals presenting severe diabetes, little is
known about the impact of neonatal STZ injection and
the ensuing mild hyperglycemia on these parameters.
Thus, the aim of the present study was to evaluate the
effect of neonatally induced mild diabetes on physical
development, behavior, and reproductive function, of
female Wistar rats from infancy to adulthood.
Methods
Subjects
The female rats used in these studies were the offspring
of male and female Wistar rats obtained from São Paulo
State University (Unesp), Botucatu, São Paulo State,
Brazil. They were maintained in an experimental room
under controlled conditions of temperature (22 ± 2°C),
humidity (50 ± 10%), and a 12 h light/dark cycle. All
experimental procedures were approved by the local
Committee of Ethics in Animal Experimentation (Number
665), which assures adherence to the standards established
by the NIH Guide for the Care and Use of Laboratory
Animals.
Experimental procedure
All experimental procedures are summarized on Figure 1.
Rats used in this study were the offspring of 16 females
that were mated at 90 days of age. The morning on which
sperm were found in the vaginal smear was designated
pregnancy day 0. Around pregnancy day 22 the rats
delivered naturally. Litters of these females were ran-
domly assigned to one of two groups. Control litters
(n = 10) in which pups received subcutaneous injections of
citrate buffer (0.1 M, pH 4.5) on first day of life (postnatal
day 0 - PND 0); and STZ litters (n = 6) in which pups
received a subcutaneous injection of 100 mg/kg strepto-
zotocin (STZ, SIGMA Chemical Company, St. Louis,
Millstone) [10,21] on PND 0. STZ or vehicle was carefully
injected in the pups to minimize leakage of solution. This
experimental model has been used successfully in several
studies to induce mild hyperglycemia [3,22-26]. The
number of pups per litter was standardized at 8 females
and pups remained with their mothers until weaning.
The mortality rate of the STZ group was 8%.
Two cohorts of rats underwent this treatment. Females
in the first cohort were used in experiment 1 to evaluate
the effects of neonatal STZ treatment on physical devel-
opment, blood glucose levels and open field behavior. In
Experiment 2 the effect of this manipulation on estrous
cyclicity, sexual behavior, and circulating levels of insulin
and reproductive hormones were assessed in females
from a separate cohort.
Effects of STZ treatment on blood glucose levels
On postnatal day (PND) 35, 84 and 120, blood samples
were obtained from a tail nick for glycemic determinations
(glucose oxidase) using a commercial glucometer (One
Touch Ultra, Johnson & JohnsonW) and values were
expressed in milligrams per deciliter (mg/dl). All animals
were tested during the light phase of the cycle, 4 to
5 hours after lights on. Rats were not fasted for glycemic
determinations.
Experiment 1: Physical development and behavior in the
open field
This STZ treatment creates a range of damage to beta
cells, leading to a variable range of insulin insufficiency
in adulthood [2]. Thus, for these measures the STZ
group was further subdivided according to the glycemic
levels measured on PND 120: STZ hyperglycemic (18
offspring from the 6 STZ-treated litters), having glycemic
levels between 120 and 300 mg/dl; and STZ normogly-
cemic littermates (14 offspring from the 6 STZ treated
litters), that had received STZ solution but had blood
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glucose levels lower than 120 mg/dL in adult life.
Where more than one pup from a litter was tested on a
measure the scores were averaged across pups so that
the litter remained the experimental unit.
Physical development
Pups from each litter were observed daily from PND 1 to
20 in order to evaluate physical development according
to the methodology proposed by Smart & Dobbing [27].
Eye opening, hair appearance, pinna unfolding, incisor
eruption, and vaginal opening were observed until 100%
of the pups in the litter reached that developmental
landmark.
Body weight and naso-anal body length were measured
on PND 0, 10 and 21. Body weight gain and change in
body length between PND 0 to 10 and 10 to 21 were
calculated. Calipers were used on PND 10 and 21 to
measure anogenital distance: the length (millimeters) from
the anal to the genital opening. Because anogenital dis-
tance can be influenced by body length an anogenital
index was calculated as anogenital distance/body length.
Open field behavior
Two open fields similar to that described by Broadhurst
[28] were used in this study. To evaluate the behavior of
rats on PND 21, the open field consisted of a wooden
circular arena with a diameter and height of 40 cm. An
arena with diameter 100 cm and height 40 cm was used
for adult rats on PND 75. The floor of both arenas was
divided into 25 approximately equal sections. All testing
was carried out in a quiet, diffusely lit room between 2
and 5 p.m during the light phase of the day/night cycle.
To minimize possible influences of circadian rhythmicity
on rat behavior in the open field, testing of control and
experimental rats was interspersed. The apparatus was
cleaned with a 5% alcohol solution between each test.
Behavior in the open field was used for assessment of
general activity on PND 21 and 75. Each animal was
placed in the arena and the following parameters were
observed for five minutes:
 Ambulation: number of sections entered with
all 4 paws;
 Rearing: number of times the animal stood on its
hind limbs;
 Immobility: time in seconds the animal did not
show motor activity and its head, trunk and limbs
remained static;
 Self-grooming: time in seconds the animal
performed this activity.
PND 0 
Birth 
PND 35 PND 84 
Glycemia
PND 120 
STZ group was further subdivided according to the 
glycemic levels measured on PND 120.  
Experimental groups: 
Control (n=10) 
STZ hyperglycemic (glycemia 120 to 300 mg/dL, n=6)  
STZ normoglycemic (glycemia below 120 mg/dL, n=6) 
Experimental design 
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Body weight 
Body length 
Anogenital
distance 
Physical 
development 
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PND 10 PND 21 PND 75 
Body weight 
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Body weight 
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Insulin 
determination 
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Estrous cycle 
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Inverted 
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Effect of STZ treatment on blood glucose levels 
Experiment 1: Physical development and behavior in the open field 
Experiment 2: Assessment of estrous cyclicity, sexual behavior and circulating gonadotropin, ovarian steroid, and insulin levels 
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Figure 1 Experimental design.
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Two observers scored the behavior using hand-operated
counters and stopwatches. The presence of urine, and
fecal boli were also recorded and analyzed.
Experiment 2: Assessment of estrous cyclicity, sexual
behavior and circulating gonadotropin, ovarian steroid,
and insulin levels
Only rats from Control (blood glucose levels lower
than 120 mg/dL) and STZ hyperglycemic (glycemic
levels between 120 and 300 mg/dL) groups were used
in this study. 2 to 3 female rats from each litter were
tested on each parameter and the scores/measures
averaged within a litter.
Estrous cycle duration
Stage of the estrous cycle was assessed by light micro-
scopic examination of cells obtained from vaginal smears
collected every morning over a period of 15 days (PND
90 to PND 105). Estrous cycle phase was estimated
based on cell type and relative frequency [29,30]. Estrous
cycle duration was calculated based on the number of
days between one estrous phase to the next.
Determination of circulating gonadatropin and ovarian
steroid concentrations
During the estrous phase of the natural estrous cycle,
blood samples were collected from the caudal vein into
heparin-coated syringes, at 09:00 a.m. Immediately after
collection, blood samples were centrifuged (2500 rpm
for 20 min at 2C) and the plasma frozen at -20C until
the assays were performed. Plasma LH and FSH were
determined by double antibody radioimmunoassay using
specific kits provided by National Hormone and Peptide
Program (National Institutes of Diseases Digestive and
Kidney, USA). The concentration of plasma progesterone
and beta-estradiol was determined by double antibody
radioimmunoassay using specific kits provided by MAIA
(BioChem ImmunoSystems, Itália S.P.A). All samples were
measured in duplicate and, when needed, at different
dilutions. All samples from the same experiment were
measured in the same assay.
Sexual behavior
Rats were maintained under controlled temperature
conditions on a reversed 12-h light–dark cycle (lights on
at 10 p.m.) for 15 days prior to the tests, with ad libitum
access to food and water. Around PND120, the mating
tests were performed according to the methodology
described by Felício and Nasello [31]. Sexual behavior was
assessed in cycling rats 3 to 4 hours after a proestrous
smear was observed. Sexually experienced males were
used in these tests which lasted until ten mounts had been
observed [32]. Results were expressed as the lordosis
quotient (LQ, number of lordosis/ ten mounts X100) [33].
All rats were tested only once.
Insulin determination and glycemia
On PND 84 blood samples were obtained for plasma
insulin determination by ELISA (MercodiaW) and values
were expressed as milligrams per liter (mg/L). On PND
120, blood samples were obtained from a tail nick for
glycemic determinations (glucose oxidase) by a usual
glucometer, and values were expressed in milligrams
per deciliter (mg/dL). All animals were tested during
the light phase of the cycle, 4 to 5 hours after lights on.
Rats were not fasted for glycemic determinations. The
mild diabetic condition was confirmed with blood glucose
concentration ranging between 120–300 mg/dL in adult
rats [34-36].
Data analysis
One-way ANOVA was used to compare timing of de-
velopmental landmarks as well as circulating hormone
levels, sexual behavior and estrous cycle length. Two-way
ANOVA with time as the within subjects measure and
group as the between subject variable followed, where
appropriate, by Tukey’s post hoc test were used to assess
change in body weight, body length, anogenital index,
glycemia and open field behavior. Fisher’s exact test was
employed to compare presence of urine and fecal boli on
the open field between groups. Statistical significance was
set at p < 0.05 for all data. All statistical analysis was
performed using SPSS (IBM, SPSS Statistics 15).
Results
Experiment 1: Physical development and behavior in the
open field
Glycemic development
The average glycemic levels of the control group on Day
120 was 105.40±2.65 compared to 130.34±1.80 for the
STZ-treated group that met the hyperglycemia criterion
and 110.93±1.57 for STZ group that did not meet that
criterion. Figure 2 shows mean blood glucose levels for
each of these groups on PNDs 35 and 84. Overall rats in
the STZ hyperglycemic group, as defined on PND 120,
also had higher blood glucose levels than the control
group at these earlier time points (significant main effect
of group F(2,19) = 4.475, p < .05; post hoc Tukey’s test
Control vs STZ hyperglycemic, p < .05). There was no
overall effect of time although the time by group inter-
action approached significance (F(2,19) = 3.44, p = 0.053)
reflecting the fact that the difference in blood glucose
levels between rats in the STZ hyperglycemic group and
the other two groups tended to increase over time.
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Physical development
There were no significant differences between Control and
STZ groups on any of the developmental landmarks
measured (Hair appearance (Control, 6.54±0.25; STZ,
7.20±0.37, F(1,14) = 0.008, p > .05); Pinna unfolding
(Control, 3.03±0.18; STZ, 3.24±0.23, F(1,14) = 0.533, p > .05);
Incisor eruption (Control, 8.83±0.21; STZ, 9.32±0.36, F
(1,14) = 0.330, p > .05); Eye opening (Control, 14.60±0.33;
STZ, 14.34±0.22, F(1,14) = <0.001, p > .05); and vaginal
opening (Control, 35.85±0.84; STZ, 35.87±0.93, F(1,14) =
1.575, p > .05).
As expected, body length, body weight, and anogenital
distance index of pups in all groups increased over time
(F(1,19) = 9.74, p < .01, F(1,19) = 19.52, p < .001, F(1,19) =
387.06, p < .001, respectively). There were no significant
differences between Control and STZ groups on body
weight gain (Figure 3A). Both groups of STZ-treated
pups showed a smaller increase in body length between
PND 0 and 10 than pups in the Control group but all
groups grew at similar rates between PND 10 and 20
resulting in a trend toward a time and group interaction
effect (F(2,19) = 3.198, p = 0.064) (Figure 3B). Both groups
of STZ treated rats had a higher anogenital index than rats
in the control group (F(2,19) = 4.73, p < .05; post hoc tukey
test control vs STZ hyperglycemic, p < .05, STZ hypergly-
cemic vs STZ normoglycemic, p < .05) probably due to the
decreased body length of STZ rats (Figure 4).
Open field behavior
Behavior in the open field for all groups on PND 21 and
75 is shown in Figure 5. Rats in the STZ hyperglycemic
group had a lower ambulation score than either of the
other two groups (Group effect, F(2,19) = 16.388, p < .05;
post hoc Tukey test Control vs STZ hyperglycemic, p < .05,
STZ hyperglycemic vs STZ normoglycemic, p < .05).
Similarly, frequency of rearing was lower in the STZ
hyperglycemic group than in the other groups (Group
effect, F(2,19) = 6.115, p < .05; post hoc tukey test control
vs STZ hyperglycemic, p < .05, STZ hyperglycemic vs STZ
normoglycemic, p < .05). On PND 75 rats in the STZ
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hyperglycemic had a higher rate of urination and increased
presence of fecal boli than rats in the other groups (Fisher’s
exact test, p < .05).
Experiment 2: Estrous cyclicity, sexual behavior and
circulating gonadotropin, ovarian steroid, and insulin levels
On PND 120 blood glucose levels of controls were
105,64±2.67 and of STZ-treated rats 132.30±2.20 (F(1,10) =
59.416, p < .05). In addition, STZ hyperglycemic rats had
lower circulating insulin levels than Control rats on PND
84 (F(1,10) = 5.012, p < .05) (Figure 6).
There were no significant differences in estrous cycle
duration (Control, 4.10±0.16; STZ, 4.62±0.31, F(1,10) =
2.281, p > .05), lordosis quotient (Control, 90.00±4.28;
STZ, 86.39±3.37, F(1,10) = 0.439, p > .05), and LH and
FSH levels (F(1,9) = 0.670, p > .05; F(1,9) = 1.253, p > .05
respectively) between the groups. However, as Figure 7
shows, STZ hyperglycemic rats tended to have higher
serum progesterone (F(1,9) = 3.878, p = 0.08) and lower
beta-estradiol levels (F(1,9) = 4.722, p = 0.058) than rats
in the Control group.
Discussion
In this study we investigated the effects of neonatal STZ
injection on a broad array of developmental and adult
measures in female rats. We observed acute effects of STZ
injection on growth and long-term consequences of this
treatment on open field behavior and on some measures
of reproductive hormones.
Hyperglycemia only appeared in a subset of the STZ
treated rats and did so only at PND 84. Both of these
effects are consistent with earlier reports (Kiss et al.,
2009). When STZ is given at such an early age the pancre-
atic beta-cells are partially restored and recovery rate
as well as degree of recovery varies between animals.
Using a similar neonatal STZ injection model, Bonner-
Weir and colleagues [1] reported that STZ-treated rats
were normoglycemic until 6 weeks of life. As in the
current study Bonner-Weir and colleagues also found
that the prolonged hyperglycemia of adult STZ rats was
associated with a decrease in insulin production.
The reduced growth of STZ animals in both normogly-
cemic and hyperglycemic groups from Days 1–10 most
probably reflects the hyperglycemia/hypoinsulinemia
induced by STZ injection. Bonner-Weir and colleagues
[1] found that rat pups injected with STZ on Day 2
postpartum showed a peak of hyperglycemia and a marked
reduction of beta-cell numbers on Day 4 postpartum.
By 10 days of age the STZ injected animals became
normoglycemic with partial recovery of the beta-cell
number. As a reduction in beta cell number leads to
hypoinsulemia and insulin is directed related to growth
[37,38], one would expect a reduction in growth during
the hypoinsulemic period. However, since between PND
10 and 21 normoglycemia was already re-established
with beta-cell number and insulin production partially
recovered, growth rate was not impaired. A change in
response to insulin, while not explaining the initial
growth retardation, could contribute to the normal growth
rate later in life in the face of lower insulin levels.
In the current study, rats in the STZ hyperglycemic
group exhibited diminished locomotor and exploratory
behaviors in adulthood compared to the control group
and this difference was associated with increased urination
and presence of fecal boli. Both of these measures are
often used as indices of anxiety and suggest higher anxiety
in the STZ hyperglycemic group than in controls. Other
authors using models similar to that used here have
Figure 6 Insulin levels on PND 84 from Control (n = 10) and STZ hyperglycemic (n = 6) rats. Values expressed as mean ± standard error of
mean. *p < 0.05 – statistically significant difference compared to Control group (One way ANOVA).
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reported these effects only in infancy [39] but reductions
in locomotor and exploratory behaviors are commonly
observed in adulthood in severely diabetic rats. For
example, Grzeda et al. reported decreased locomotor
and exploratory activity in the open field in diabetic
rats [12]. In addition, several studies of severely diabetic
rats report a reduction in the frequency of crossings
and rearings in the open field [11-15]. In another study,
Bellush and colleagues [11] demonstrated that diabetic
rats showed decreased locomotion only on the first
exposure to an open field suggesting that diabetes-
induced disruptions in open-field activity are related
to anxiety rather than to motor or energy deficits. In
addition, Ramanathan and colleagues [13,14] showed that
diabetic rats were more anxious than non-diabetic animals
in the open field, elevated plus maze and social interaction
test. In the current study only the hyperglycemic STZ-
treated rats showed these changes in open field behavior
suggesting that it was the long term consequences of
this early manipulation on metabolism rather than the
early manipulation per se that induced these behavioral
changes. ln conclusion, the open field results for the
mild hyperglycemic rats from the present study are in
agreement with several studies using severely diabetic
rats, suggesting that glycemic levels do not necessarily
have to exceed 300 mg/dL to impair behavior in both
infancy and adult life.
It is well established that diabetes impairs reproductive
function [16,17] and embryonic development [40,41].
Results of several studies have demonstrated an impaired
LH surge in severely diabetic rats [42-45] although basal
levels of LH and FSH levels did not differ between diabetic
and nondiabetic rats [46,47]. Consistent with the latter
findings, in the current study hyperglycemia was not
associated with any change in circulating gonadotropins.
However, again similar to the result of studies of severely
diabetic animals [48] ovarian hormone levels were altered
.in hyperglycemic STZ-treated rats.
One possible explanation for this is the role of insulin
in modulating ovarian steroid production. It is well-
established that both insulin and IGF-I synergize with
gonadotropins to enhance granulosa cell function [49,50]
and lack of insulin may interfere with the action of gonad-
otropins on granulosa cells [47] and impair the synthesis
Figure 7 Sexual hormones levels of Control (n = 10) and STZ hyperglycemic (n = 6) rats. Values expressed as mean ± standard error of
mean. # p < 0.10 compared to Control group (ANOVA).
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of ovarian hormones (see [51], for a general review in
mammals). Such a mechanism would not however,
explain the higher levels of progesterone and lower
levels of beta-estradiol in the STZ rats of the present
study. An alternative mechanism in which diabetes either
inhibits the conversion of progesterone to testosterone
or the aromatization of testosterone to estradiol has
been suggested by Meurer and colleagues [47] and such
a mechanism would explain the current data.
In addition to hormonal changes, severely diabetic rats
present other reproductive deficits including alterations in
the estrous cycle such as anovulation [48,52] and increases
in cycle length [53]. Lower lordosis quotients in sexual
behavior tests have also been reported [18,19]. Estrous
cycle duration and sexual behavior were not impaired
in the STZ rats in the present study. The fact that mild
hyperglycemic rats from the present study did not show
the same reproductive impairment as severe diabetic rats
reinforces the idea that the impairment of reproductive
function is dependent on the intensity of hyperglycemia.
In the current study, STZ injection in the neonatal
period caused hyperglycemia/hypoinsulinemia in adult life.
Lack of insulin on the first days following STZ injection
probably contributed to reduced growth rate, and the
re-establishment of normal growth most likely reflected
the partially recovery of insulin production. Hyperglycemic
STZ-treated rats exhibited diminished locomotor and
exploratory behavior in the open field in adulthood.
Mild hyperglycemia did not impair gonadotropin levels
although ovarian steroid hormone levels were altered.
The changes in general activity and hormone profile
observed in mild hyperglycemia are similar to those
shown in studies of severely diabetic animals. Overall
these data suggest that even mild hyperglycemia/
hypoinsulinemia is sufficient to impair general activity and
sexual steroid hormone secretion in female Wistar rats.
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